Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ARCTthis companyArcturus Therapeutics Holdings Inc.	$10.44	-2.55×	0.78×	2.5×	0.61×	-144.1%	95.5%	-111.5%	-97.9%	-30.7%	-31.4%	-44.2%	0.12×	3.28×	0×	6.64×	0.0%	1	-0.72	2	C
ABUSArbutus Biopharma Corp	$3.67	-28.29×	12.04×	65.44×	-27.47×	-163.1%	97.4%	-192.1%	-237.9%	-43.7%	-30.3%	-4.3%	0.05×	0.42×	-278.88×	15.73×	0.0%	5	28.57	4	A-
AVIRAtea Pharmaceuticals, Inc.	$4.42	-1.84×	1.06×	0×	-1.19×	-75.3%	0.0%	0.0%	0.0%	-57.5%	-63.0%	-45.4%	0×	0.58×	0×	7.82×	0.0%	2	1.99	3	B-
BNTCBenitec Biopharma Inc.	$9.28	-13.65×	3.52×	0×	-8.75×	-68.5%	0.0%	0.0%	0.0%	-25.7%	-28.8%	-2.7%	0×	3.53×	0×	34×	0.0%	1	43.49	2	C+
INOInovio Pharmaceuticals, Inc.	$1.41	-0.96×	3.39×	1,248.52×	-0.57×	-63.4%	100.0%	-132871.3%	-130000.0%	-352.5%	-259.4%	-109.0%	0.39×	0.43×	0×	1.4×	0.0%	0	-54.95	1	C-
NVAXNovavax, Inc.	$10.64	2.47×	-8.52×	0.97×	2.23×	-870.5%	93.7%	50.1%	39.2%	-344.7%	78.0%	-23.0%	-1.95×	0.02×	24.98×	2.13×	0.0%	1	-5.75	2	B-
Peer median	—	-1.84×	3.39×	0.97×	-1.19×	-75.3%	93.7%	0.0%	0.0%	-57.5%	-30.3%	-23.0%	0×	0.43×	0×	7.82×	0.0%	1	1.99	2	—